Citations

Mayo Clinic

Clear

16258 citation(s) found for "Ha, David R".

P3‐107: Shanghai community brain health initiative: Pilot study. Neuropsychological results
Ding, Ding , Guo, Qihao , Mortimer, James A., Copenhaver, Cathleen, Salmon, David P. , Petersen, Ron, Borenstein, Amy R., Zhao, Qianhua , Ding, Ding , Galasko, Douglas , DeCarli, Charles , Dai, Qi , Wu, Yougui , Hong, Zhen

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_12 | Pages: No page available

10.1016/j.jalz.2009.04.1082 Get It

Prospective Comparison of State-of-the-Art MR Enterography and CT Enterography in Small-Bowel Crohn's Disease
Siddiki, Hassan , Fidler, Jeff L. , Burton, Sharon S., Huprich, James E., Hough, David M., Johnson, C. Daniel, Bruining, David H. , Loftus, Edward V. , Sandborn, William J. , Pardi, Darrell S. , Mandrekar, Jayawant N. , Fidler, Jeff L. , Fletcher, Joel G. , Loftus, Edward V

American Journal of Roentgenology | June 19, 2009 | Volume: 193 | Issue: 1 | Pages: 113-121

10.2214/ajr.08.2027 | PMID 19542402 Get It

Statistical Approach To Estimate Vaccinia-Specific Neutralizing Antibody Titers Using a High-Throughput Assay
Kennedy, Richard B. , Swanson, Eric , Watson, David , Golding, Hana , Pankratz, V. Shane , Poland, Gregory A. , Kennedy, Richard

Clinical and Vaccine Immunology | June 18, 2009 | Volume: 16 | Issue: 8 | Pages: 1105-1112

10.1128/cvi.00109-09 | PMID 19535540 Get It

ABSTRACT Because of the bioterrorism threat posed by agents such as variola virus, considerable time, resources, and effort have been devoted to biodefense preparation. One avenue of this research has been the development of rapid, sensitive, high-throughput assays to validate immune responses to poxviruses. Here we describe the adaptation of a β-galactosidase reporter-based vaccinia virus neutralization assay to large-scale use in a study that included over 1,000 subjects. We also describe the statistical methods involved in analyzing the large quantity of data generated. The assay and its associated methods should prove useful tools in monitoring immune responses to next-generation smallpox vaccines, studying poxvirus immunity, and evaluating therapeutic agents such as vaccinia virus immune globulin.
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
Steensma, David P. , Baer, Maria R. , Slack, James L., Buckstein, Rena , Godley, Lucy A. , Garcia‐Manero, Guillermo , Albitar, Maher , Larsen, Julie S., Arora, Sujata, Cullen, Michael, Kantarjian, Hagop M. , Godley, Lucy A , Steensma, David P , Kantarjian, Hagop

Journal of Clinical Oncology | June 16, 2009 | Volume: 27 | Issue: 23 | Pages: 3842-3848

10.1200/jco.2008.19.6550 | PMID 19528372 Get It

Purpose Decitabine, a DNA-targeted hypomethylating agent, is approved by the United States Food and Drug Administration for treatment of patients with myelodysplastic syndromes (MDS) on a schedule of 15 mg/m2 administered via intravenous (IV) infusion every 8 hours for 3 days. This study assessed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in academic and community-based practices. Patients and Methods Patients were treated with decitabine 20 mg/m2 by IV infusion daily for 5 consecutive days every 4 weeks. Eligible patients were ≥ 18 years of age and had MDS (de novo or secondary) of any French-American-British (FAB) subtype and an International Prognostic Scoring System (IPSS) score ≥ 0.5. The primary end point was the overall response rate (ORR) by International Working Group (IWG 2006) criteria; secondary end points included cytogenetic responses, hematologic improvement (HI), response duration, survival, and safety. Results Ninety-nine patients were enrolled; the ORR was 32% (17 complete responses [CR] plus 15 marrow CRs [mCRs]), and the overall improvement rate was 51%, which included 18% HI. Similar response rates were observed in all FAB subtypes and IPSS risk categories. Among patients who improved, 82% demonstrated responses by the end of cycle 2. Among 33 patients assessable for a cytogenetic response, 17 (52%) experienced cytogenetic CR (n = 11) or partial response (n = 6). Conclusion Decitabine given on a 5-day schedule provided meaningful clinical benefit for patients with MDS, with more than half demonstrating improvement. This suggests that decitabine can be administered in an outpatient setting with comparable efficacy and safety to the United States Food and Drug Administration–approved inpatient regimen.
Steady Expiratory Flow-Pressure Relationship in a Model of the Human Bronchial Tree
Reynolds, David

Journal of Biomechanical Engineering | June 15, 2009 | Volume: 104 | Issue: 2 | Pages: 153-158

10.1115/1.3138330 | PMID 7078131 Get It

Static pressure differences across a human bronchial tree model were obtained for steady expiratory flows of several gases producing Reynolds numbers (Re1) in the bronchus carrying the entire flow (first bronchus) between 150 and 50,000. The model was constructed from an air-dried lung and was complete to bronchi about 2 mm in diameter. Dimensionless static pressure plotted against Re1 consolidated the data on a single curve, phenomenologically described by an equation of the form: ΔPs/ΔPd1 = A + B Re1 where ΔPd1 is a pressure drop for Poiseuille flow. Velocity profile measurements at two sites along the first bronchus for laminar and turbulent flows indicate a dependence on the latter and distance from the first junction. Loss in total pressure was computed and may result from both frictional dissipation and changes in momentum flux associated with development of velocity profiles near the junctions. An average loss in total pressure within a single bronchus was calculated after making several simplifying assumptions, and this result may be useful in modeling both the resistance of the entire bronchial tree and the more complex phenomenon of maximal expiratory flow.
Donepezil delays progression to AD in MCI subjects with depressive symptoms
LU, PO‐LIANG, Edland, Steven D. , Teng, Edmond , Tingus, Kathleen, Petersen, Ronald C. , DeKosky, Steven T. , Darvesh, Sultan , Hogan, David B. , Cummings, Jeffrey L.

Neurology | June 15, 2009 | Volume: 72 | Issue: 24 | Pages: 2115-2121

10.1212/wnl.0b013e3181aa52d3 | PMID 19528519 Get It

Quantitation of Serum Monoclonal Proteins: Relationship between Agarose Gel Electrophoresis and Immunonephelometry
Murray, David , Ryu, Euijung , Snyder, Melissa R, Katzmann, Jerry A., Snyder, Melissa R

Clinical Chemistry | June 11, 2009 | Volume: 55 | Issue: 8 | Pages: 1523-1529

10.1373/clinchem.2009.124461 | PMID 19520759 Get It

Abstract Background: Previous comparisons of monoclonal protein quantification identified a bias between serum protein electrophoresis (SPEP) and immunonephelometry (NEPH). Methods: We reviewed data from 2845 patients in whom a single sample provided a γ fraction M-spike by SPEP, a heavy chain isotype by immunofixation electrophoresis (IFE), and an Ig quantification by NEPH. We examined the relationship between SPEP and NEPH. Selected sera with high monoclonal protein concentrations were diluted and reassessed. Results: For all isotypes, the relationship between SPEP and NEPH was best fitted with cubic curves. We determined the concentrations of each isotype that fitted a linear relationship. IgA had the best correspondence (slope 0.92, 95% CI 0.87–1.02), whereas IgM demonstrated a systematic bias of higher values by NEPH (slope 1.80, 95% CI 1.68–1.92). IgG demonstrated a nonlinear relationship between SPEP and NEPH, with a linear region <19.2 g/L having a slope of 0.83 (95% CI 0.79–0.89) and a second linear region having a slope of 1.47 (95% CI 1.39–1.53) at higher concentrations. Dilutions of high-concentration IgG monoclonal proteins were linear by NEPH and nonlinear by SPEP. Conclusions: There are systematic differences in the quantification of monoclonal IgM and IgG by SPEP and NEPH. The bias in IgM is from NEPH overestimation. The nonlinearity of SPEP at high monoclonal IgG concentrations may obscure changes in plasma cell populations. Clinicians should be made aware of the biases and nonlinearity in these tests to make proper conclusions regarding treatment response.
Phenotypic variation in Actinobacillus actionmycetemcomitans during laboratory growth: implications for virulence
Furgang, David, Schreiner, Helen, Goncharoff, P, Charlesworth, Jon E. , Ghazwan, Ghazi, Fitzgerald-Bocarsly, Patricia, Figurski, David H., Fine, Daniel H. , Fitzgerald‐Bocarsly, Patricia

Microbiology | June 5, 2009 | Volume: 145 | Issue: 6 | Pages: 1335-1347

10.1099/13500872-145-6-1335 | PMID 10411260 Get It

Structural Basis of Ist1 Function and Ist1–Did2 Interaction in the Multivesicular Body Pathway and Cytokinesis
Xiao, Junyu , Chen, Xiaowei , Davies, Brian A., Saltiel, Alan R. , Katzmann, David J. , Xu, Zhaohui

Molecular Biology of the Cell | May 29, 2009 | Volume: 20 | Issue: 15 | Pages: 3514-3524

10.1091/mbc.e09-05-0403 | PMID 19477918 Get It

The ESCRT machinery functions in several important eukaryotic cellular processes. The AAA-ATPase Vps4 catalyzes disassembly of the ESCRT-III complex and may regulate membrane deformation and vesicle scission as well. Ist1 was proposed to be a regulator of Vps4, but its mechanism of action was unclear. The crystal structure of the N-terminal domain of Ist1 (Ist1NTD) reveals an ESCRT-III subunit-like fold, implicating Ist1 as a divergent ESCRT-III family member. Ist1NTD specifically binds to the ESCRT-III subunit Did2, and cocrystallization of Ist1NTD with a Did2 fragment shows that Ist1 interacts with the Did2 C-terminal MIM1 (MIT-interacting motif 1) via a novel MIM-binding structural motif. This arrangement indicates a mechanism for intermolecular ESCRT-III subunit association and may also suggest one form of ESCRT-III subunit autoinhibition via intramolecular interaction.
Decisions, Decisions
Steensma, David P. , Steensma, David P

The Oncologist | May 28, 2009 | Volume: 14 | Issue: 6 | Pages: 640-641

10.1634/theoncologist.2009-0081 Get It

Abstract The author comments on van Laarhoven et al.’s reflection on the motives behind medical decision making.